Immune responses require a delicate balance: a weak response can cause immunodeficiency, whereas an excessive response can lead to hyperinflammatory disease and hematological malignancy. Because spleen tyrosine kinase has roles in multiple signaling pathways, its gain-of-function alterations in humans cause hypogammaglobulinemia as well as autoinflammation and predisposition to B cell lymphoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$79.00
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.

References
LeBien, T. W. & Tedder, T. F. Blood 112, 1570–1580 (2008).
Mócsai, A., Ruland, J. & Tybulewicz, V. L. Nat. Rev. Immunol. 10, 387–402 (2010).
Wang, L. et al.. Nat. Genet. https://doi.org/10.1038/s41588-021-00803-4 (2021).
Turner, M. et al. Nature 378, 298–302 (1995).
Cheng, A. M. et al. Nature 378, 303–306 (1995).
Grammatikos, A. P., Ghosh, D., Devlin, A., Kyttaris, V. C. & Tsokos, G. C. PLoS ONE 8, e74550 (2013).
Csete, D. et al. Front. Immunol. 10, 937 (2019).
Tao, L. & Reese, T. A. Trends Immunol 38, 181–193 (2017).
De Roos, A. J. et al. Cancer Res. 72, 4733–4743 (2012).
Krisenko, M. O. & Geahlen, R. L. Biochim. Biophys. Acta 1853, 254–263 (2015).
Chen, L. et al. Cancer Cell 23, 826–838 (2013).
Herishanu, Y. et al. Blood 117, 563–574 (2011).
Genovese, M. C. et al. J. Rheumatol. 41, 4120–4128 (2014).
Newland, A. & McDonald, V. Immunotherapy 12, 1325–1340 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Aksentijevich, I. The sickening consequences of too much SYK signaling. Nat Genet 53, 432–434 (2021). https://doi.org/10.1038/s41588-021-00837-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-021-00837-8
This article is cited by
-
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
Clinical Pharmacokinetics (2022)